Assembly Biosciences (NASDAQ:ASMB) Trading 4% Higher – Here’s What Happened

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) were up 4% during trading on Wednesday . The company traded as high as $33.06 and last traded at $33.4250. Approximately 21,173 shares were traded during mid-day trading, a decline of 73% from the average daily volume of 77,868 shares. The stock had previously closed at $32.13.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ASMB. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research report on Monday, December 22nd. Mizuho set a $40.00 price target on shares of Assembly Biosciences and gave the company an “outperform” rating in a research report on Thursday, November 20th. Citigroup began coverage on shares of Assembly Biosciences in a research report on Wednesday, September 24th. They set an “outperform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, October 8th. Finally, JMP Securities assumed coverage on shares of Assembly Biosciences in a report on Wednesday, September 24th. They set a “market outperform” rating and a $38.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Assembly Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $41.00.

Assembly Biosciences Stock Performance

The company’s 50-day moving average price is $33.93 and its 200-day moving average price is $26.30. The firm has a market capitalization of $524.92 million, a PE ratio of -6.93 and a beta of 1.14.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.22). The company had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $7.46 million. Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%. As a group, analysts anticipate that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current year.

Institutional Investors Weigh In On Assembly Biosciences

Several large investors have recently modified their holdings of the company. American Century Companies Inc. acquired a new stake in Assembly Biosciences during the 1st quarter worth $113,000. Acadian Asset Management LLC boosted its stake in shares of Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares during the period. Palumbo Wealth Management LLC grew its holdings in shares of Assembly Biosciences by 3.8% during the second quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock worth $338,000 after buying an additional 681 shares during the last quarter. Geode Capital Management LLC increased its position in Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 3,312 shares during the period. Finally, Ellsworth Advisors LLC purchased a new stake in Assembly Biosciences during the 3rd quarter valued at approximately $852,000. 19.92% of the stock is owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.